Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development-stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the EMERGE Phase 2 trial. Vopratelimab will also be evaluated in the Phase 2 SELECT trial in combination with Jounce’s internal investigational PD-1 inhibitor, JTX-4014, in biomarker selected patients using TISvopra. Jounce’s next clinical candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. Additionally, Jounce has agreed to exclusively license worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences. For more information, please visit www.jouncetx.com.
Location: United States, Massachusetts, Cambridge
Phone: +1 857-259-3840
Total raised: $159.3M
Investors 2
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Omega Fund... | omegafunds... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.03.2021 | - | $56.3M | - |
| 23.04.2015 | Series B | $56M | - |
| 14.02.2013 | Series A | $47M | Third Rock... |
Mentions in press and media 22
| Date | Title | Description |
| 03.04.2023 | Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc | /EIN News/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, ... |
| 15.03.2023 | Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 14, 2023 (GLOBE NE... |
| 20.10.2022 | Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Co... | - Two preclinical posters highlighting the JTX-1484 program and LILRB family at SITC 2022 - - Two clinical posters highlighting data from the SELECT and INNATE trials at ESMO-IO - CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Jounce T... |
| 10.01.2022 | Jounce Therapeutics : Corporate Presentation | Jounce Therapeutics Corporate Presentation A NEXT GEN IMMUNOTHERAPY COMPANY JANUARY 2022 Legal Disclaimer Various statements concerning our future expectations, plans and prospects, including without limitation, our expectations regarding f... |
| 09.03.2021 | Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock | CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that... |
| 01.09.2020 | Gilead inks $805M in-licensing deal with Jounce for preclinical immuno-oncology drug | Shares of Jounce rose 65.5% on the Nasdaq when markets opened Tuesday and were still up more than 47% in late-morning trading. Gilead’s shares fell by 2.5%. JTX-1811 is a monoclonal antibody that targets the chemokine receptor CCR8, thereby... |
| 27.01.2017 | Jounce Therapeutics prices IPO beyond expectations (Updated) | The early stage biotech company, with a focus on cancer immunotherapy and targeted therapeutics, has raised $102 million in private funding to date, from investors such as Third Rock. Jounce is listed on the NASDAQ Capital Market under the ... |
| 27.01.2017 | Jounce Therapeutics Prices IPO to Raise $101.84M | Jounce Therapeutics, Inc., a Cambridge, MA-based clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, priced its initial public offering of 6,365,000 shares of common sto... |
| 27.01.2017 | Term Sheet — Friday, January 27 | MOVING ON, MOVING UP, MOVING OUT Gone: Marc Lore has wasted no time shaking up Walmart’s ecommerce operations. He became president and CEO of Walmart eCommerce U.S. last August, when the company acquired his startup, Jet.com. Paid Content H... |
| 30.12.2016 | Jounce Therapuetics registers for a 2017 IPO | Jounce plans to list on the NASDAQ Capital Market using the ticker symbol “JNCE.” At its upper limit, the startup could raise $75 million through the IPO. That’s a tidy sum for a company that launched as recently as Feb. 2013, with the back... |
Show more